Form 4 for FTH Faeth Therapeutics, Inc.

Accepted 2024-02-16 00:00:00 ET · period of report 2024-02-15 · accession 0001415889-24-004236 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2024-02-16	2024-02-15	FTH	van der Horst Edward	CSO	F - Tax	$0.79	-2,843	56.1K	-5%	-$2,246
DM	2024-02-16	2024-02-15	FTH	van der Horst Edward	CSO	A - Grant	$0.00	+215.1K	90.1K	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2024-02-15	F	D	2,843	$0.79	56,070	D	—	—	(F2) Includes an aggregate of 6,000 shares purchased by the Reporting Person since May 16, 2023 pursuant to the Issuer's 2021 Employee Stock Purchase Plan.
2	Derivative	Stock Option (Right to Buy)	2024-02-15	A	A	125,000	$0.00	125,000	D	$0.79 · — to 2034-02-14	125,000 Common Stock	(F3) The option shall vest over a period of four years as follows: 25% of the total number of shares subject to the option shall vest on February 15, 2025, and the remainder will vest 1/48th of total number of shares subject to the option monthly thereafter over the remaining three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.
3	Derivative	Stock Option (Right to Buy)	2024-02-15	A	A	90,102	$0.00	90,102	D	$0.79 · — to 2034-02-14	90,102 Common Stock	(F4) Represents one-third of the Reporting Person's 2023 annual bonus, which the Compensation Committee of the Issuer determined to pay in the form of a stock option in lieu of cash. 100% of the shares are fully vested as of the date of grant.